A phase I trial of HER2-targeted NK-92/5.28.z cells in recurrent glioblastoma demonstrated no severe toxicities and induced stable disease in five patients, with CD8+ T-cell infiltration correlating with longer progression-free survival [293]. The gene discussed is ERBB2; the disease is glioblastoma.